ArticleScience advances2019
Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 85 citations in OpenAlex.
- Unveiling Mucorales infections: A cutting-edge longitudinal imaging approach for real-time infection and host-response monitoring inVirulence · 2026Article
- Comparative Proteomics of Extracellular Vesicles of Two Species of Mucorales Reveals Species-Specific Cargo.Mycopathologia · 2026Article
- Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis.Journal of fungi (Basel, Switzerland) · 2026Article
- WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threats.The Lancet. Microbe · 2026Review
- Molecular Mechanisms of Mucormycosis Pathogenesis: Host-Pathogen Interactions and Immune Evasion.Pathogens (Basel, Switzerland) · 2026Review
- Rapid and reliable diagnosis of mucormycosis using colorimetric loop-mediated isothermal amplification.Journal of clinical microbiology · 2026Article
- Secondary fungal infections in severe acute viral diseases: clinical features and underlying immune mechanisms.Frontiers in microbiology · 2026Review
- The expression of fungal CotH, human glucose-regulated protein 78 (GRP78), and predicted miRNAs in macrophages and diabetic mice infected withMicrobiology spectrum · 2025Article
- Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.The Journal of antimicrobial chemotherapy · 2025Review
- A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response.Science translational medicine · 2025Article
- The Contribution of Human Antimicrobial Peptides to Fungi.International journal of molecular sciences · 2025Review
- A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori.PloS one · 2025Article
- Mucormycosis and COVID-19: Unraveling the Interplay of Fungal Infection in a Global Health Crisis: An Overview.Infectious disorders drug targets · 2025Review
- Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.Annals of medicine · 2024Review
- Naamidine A reveals a promising zinc-binding strategy for topical antifungal therapy.Antimicrobial agents and chemotherapy · 2024Article
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Immunity to fungi and vaccine considerations.Cell host & microbe · 2024Review
- Multiple roles for hypoxia inducible factor 1-alpha in airway epithelial cells during mucormycosis.Nature communications · 2024Article
- Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.Antimicrobial agents and chemotherapy · 2024Article
- Mucormycosis: A Rare disease to Notifiable Disease.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Teclegiorgis GebremariamLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Sondus AlkhazrajiLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Sameh S M SolimanSharjah Institute for Medical Research, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
Yiyou GuLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Heewon H JeonLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Lina ZhangLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Samuel W FrenchLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
David A StevensCalifornia Institute for Medical Research, San Jose, CA, USA.
John E EdwardsLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.ORCID 0000-0001-7608-6021
Scott G FillerLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.ORCID 0000-0001-7278-3700
Priya UppuluriLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Ashraf S IbrahimLos Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, USA.ORCID 0000-0003-3787-8530
UCLA Medical Center · USUniversity of California, Los Angeles · USCalifornia Institute for Medical Research · USUniversity of Sharjah · AE
Funding
Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3MHumanized monoclonal antibodies to treat mucormycosisR43AI138904 · NIAID · VITALEX BIOSCIENCES, LLC · PI IBRAHIM, ASHRAF S., LAZAR, GARY · 2018 to 2019
$600kDevelopment of Immunotherapeutic Strategies to Overcome Neonatal CandidiasisR21HD097480 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI UPPULURI, PRIYA · 2019 to 2020
$446kNIAID NIH HHS R01 AI063503NIAID NIH HHS R43 AI138904NICHD NIH HHS R21 HD097480
Abstract
Mucorales are fungal pathogens that cause mucormycosis, a lethal angioinvasive disease. Previously, we demonstrated that
Indexed as
AnimalsAntibodies, FungalAntibodies, MonoclonalAntifungal AgentsCombined Modality TherapyDiabetic KetoacidosisDisease Models, AnimalEndoplasmic Reticulum Chaperone BiPFungal ProteinsGene ExpressionHeat-Shock ProteinsHost-Pathogen InteractionsHumansImmunization, PassiveImmunocompromised HostMaleAntibodies, FungalAntibodies, MonoclonalAntifungal AgentsEndoplasmic Reticulum Chaperone BiPFungal ProteinsHeat-Shock ProteinsHSPA5 protein, humanHspa5 protein, mouseopsonin receptorReceptors, Immunologic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.